大行评级｜瑞银：中生制药管理层对凝血因子VIIa入选医保目录感乐观 评级“买入”
SINO BIOPHARM(HK:01177) Ge Long Hui·2026-01-14 02:33Group 1 - UBS report indicates that the management of China Biopharmaceutical requires more time to finalize the guidance for its out-licensing (BD) business development this year [1] - Management is optimistic about the inclusion prospects of coagulation factor VIIa in the 2025 National Medical Insurance Drug List negotiations [1] - Penpulimab has successfully entered the medical insurance directory for the first time; anlotinib has been approved for expansion to first-line treatment of soft tissue sarcoma without any price reduction, while Yilishu benefits from an expanded reimbursement scope [1] Group 2 - UBS currently assigns a "Buy" rating to the company with a target price of HKD 12.2 [1]